A Cross-Sectional Study on The Prevalence of Anemia in Maintenance Hemodialysis and Peritoneal Dialysis Patients and Its Related Factors
Download PDF


Peritoneal dialysis
Related factors
Cross-sectional study



Submitted : 2024-02-23
Accepted : 2024-03-09
Published : 2024-03-24


Objective: To study the prevalence of anemia, the proportion of hemoglobin (Hb) levels, the treatment methods, and the influencing factors of Hb levels in maintenance hemodialysis (MHD) and peritoneal dialysis patients. Methods: In this study, 602 patients with maintenance hemodialysis and continuous ambulatory peritoneal dialysis were enrolled from December 2020 to December 2022 in our hospital, and their medical records were collected and summarized. The main contents included the patient’s gender, age, primary disease, dialysis duration, dialysis method, the use of erythropoietic stimulating agents (ESA), intravenous iron, and laboratory tests. A Hb index exceeding 110 g/L was set as the standard for the prevalence of anemia. Results: The rate of anemia in patients undergoing blood purification was 83%. The proportion of ESA use was 84.1%, and the proportion of iron use was 76.7%, of which the proportion of intravenous iron used was 17.0%, and the proportion of folic acid used was 28.3%. Conclusion: The incidence of anemia in MHD patients was relatively high, with a low proportion of patients reaching the standard Hb levels. Risk factors include albumin (ALB) levels, iron storage, white blood cells, C-reactive protein, cholesterol, etc. Nutritional support, iron supplementation, and prevention of micro-inflammatory reactions can effectively promote the improvement of Hb indicators in dialysis patients to prevent anemia.


Sun L, Yao L, 2020, Management and Treatment of Renal Anemia in Dialysis Patients. Chinese Journal of Practical Internal Medicine, 40(11): 890–894.

Su S, Xu Z, 2020, Factors Affecting the Therapeutic Effect of Renal Anemia. Chinese Journal of Practical Internal Medicine, 40(11): 916–919.

KDOQI, 2007, KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target. American Journal of Kidney Diseases, 50(3): 471–530.

Kuragano T, Matsumura O, Matsuda A, et al., 2014, Association Between Hemoglobin Variability, Serum Ferritin Levels, and Adverse Events/Mortality in Maintenance Hemodialysis Patients. Kidney International, 86(4): 845–854.

Xing X, Zhang W, Sun H, 2016, Role of Erythropoietin in Renal Anemia Therapy. Tropical Journal of Pharmaceutical Research, 15(5): 1083.

Heras-Benito M, 2023, Renal Anemia: Current Treatments and Emerging Molecules. Revista Clínica Española (English Edition), 223(7): 433–439.

Hang Y, Zhu H, Miao L, 2022, Clinical Application and Monitoring of Intravenous Iron. Journal of Clinical Pharmacotherapy, 20(12): 24–28.

Yin S, Du Y, Guo Y, et al., 2022, Multifactorial Analysis of Renal Anemia-Associated Substandard Hemoglobin Levels and Prevalence of Anemia in Patients on Maintenance Hemodialysis in Liaoning Province: A Cross-Sectional Study. Annals of Palliative Medicine, 11(12): 3743.